GH Research (GHRS)
The price, the headline numbers and the latest news, in one place.
GH Research (GHRS) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | 2.04B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.27M |
| 1.29 | |
| -0.98 | |
| n/a | |
| -16.07 | |
| P/B (ttm) | 5.68 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | n/a |
| Volume | 238,660 |
| Avg. Volume (20D) | 302,648 |
| Open | 30.00 |
| Previous Close | 29.98 |
| Day's Range | 29.05 - 30.26 |
| 52-Week Range | 11.83 - 31.44 |
| Analyst | Strong Buy |
| Price Target | 40 (34.54%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GHRS
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develo...
Financial Performance
In 2025, GH Research's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -48.26M, an increase of 23.86%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for GHRS stock is "Strong Buy". The 12-month stock price forecast is 40, which is upside of 34.54% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
